BR0012865A - Uma forma amorfa aperfeiçoada da proxetil cefpodoxima - Google Patents
Uma forma amorfa aperfeiçoada da proxetil cefpodoximaInfo
- Publication number
- BR0012865A BR0012865A BR0012865-1A BR0012865A BR0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A BR 0012865 A BR0012865 A BR 0012865A
- Authority
- BR
- Brazil
- Prior art keywords
- amorphous form
- improved
- cefpodoxime proxetil
- improved amorphous
- proxetyl
- Prior art date
Links
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 title 1
- -1 2-amino- 4-thiazolyl Chemical group 0.000 abstract 4
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 abstract 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229960005090 cefpodoxime Drugs 0.000 abstract 1
- 125000004494 ethyl ester group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1036DE1999 IN191496B (enExample) | 1999-07-30 | 1999-07-30 | |
| PCT/IB2000/001024 WO2001009143A1 (en) | 1999-07-30 | 2000-07-24 | An improved amorphous form of cefpodoxime proxetil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012865A true BR0012865A (pt) | 2002-07-09 |
Family
ID=11092065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012865-1A BR0012865A (pt) | 1999-07-30 | 2000-07-24 | Uma forma amorfa aperfeiçoada da proxetil cefpodoxima |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6602999B1 (enExample) |
| EP (1) | EP1204667A4 (enExample) |
| JP (1) | JP2003506329A (enExample) |
| CN (1) | CN1371381A (enExample) |
| AU (1) | AU5839100A (enExample) |
| BR (1) | BR0012865A (enExample) |
| IN (1) | IN191496B (enExample) |
| WO (1) | WO2001009143A1 (enExample) |
| ZA (1) | ZA200200692B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT408226B (de) * | 1999-05-05 | 2001-09-25 | Biochemie Gmbh | Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2 |
| WO2002068429A1 (en) * | 2001-02-27 | 2002-09-06 | Ranbaxy Laboratories Limited | Process for the preparation of cefpodoxime proxetil |
| CN101039906A (zh) * | 2004-10-18 | 2007-09-19 | 特瓦制药工业有限公司 | 通过将盐溶解于有机溶剂并除去该溶剂来制备无定形阿托伐他汀半钙的方法，所述有机溶剂为醇和酮和 /或酯的混合物 |
| CA2609296A1 (en) * | 2005-05-16 | 2006-11-16 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising a cephalosporin |
| KR100840132B1 (ko) * | 2007-04-17 | 2008-06-23 | 재단법인서울대학교산학협력재단 | 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조 |
| KR20150053963A (ko) * | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| WO2017046756A1 (en) * | 2015-09-18 | 2017-03-23 | Lupin Limited | Proxetil and axetil esters of cefixime |
| US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| WO2017193914A1 (zh) * | 2016-05-09 | 2017-11-16 | 苏州科睿思制药有限公司 | 克立硼罗游离形式的晶型及其制备方法和用途 |
| JP2019518058A (ja) * | 2016-06-16 | 2019-06-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | スピロ−オキシインドール化合物の固体状態形 |
| EP3510021A1 (en) * | 2016-09-06 | 2019-07-17 | Indena S.p.A. | Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| IL288737B (en) * | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| WO2018178133A1 (en) * | 2017-03-30 | 2018-10-04 | Merck Patent Gmbh | Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| KR102777452B1 (ko) * | 2017-11-22 | 2025-03-10 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 |
| KR20210003780A (ko) * | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| CN110251467A (zh) * | 2019-06-26 | 2019-09-20 | 北京济美堂医药研究有限公司 | 一种无定形态头孢妥仑匹酯组合物的制备方法 |
| CN110437259B (zh) * | 2019-08-14 | 2021-12-07 | 中国药科大学 | 头孢泊肟酯柚皮素共无定形物及其制备方法 |
| JP2022551439A (ja) * | 2019-10-04 | 2022-12-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ａｘｌ阻害薬製剤 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| EP4530380A1 (en) | 2022-05-23 | 2025-04-02 | Nagoya Institute Of Technology | Method for continuously producing biodegradable fiber material containing inorganic filler particles using wet spinning, and cotton-like bone regeneration material produced with said method |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4223153A (en) | 1979-02-09 | 1980-09-16 | Eli Lilly And Company | Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea |
| IT1165253B (it) | 1979-07-12 | 1987-04-22 | Blasinachim Spa | Procedimento di fabbricazione di acido chenodesossicolico cristallino puro |
| US4486425A (en) | 1980-09-30 | 1984-12-04 | Sankyo Company Limited | 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates |
| YU44680B (en) | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| ATE262533T1 (de) * | 1991-09-07 | 2004-04-15 | Aventis Pharma Gmbh | Diastereomer des 3-cephem-4-carbonsäure-1-(- isopropoxycarbonyloxy)ethylesters und verfahren zu dessen herstellung |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| AT413383B (de) * | 1998-01-09 | 2006-02-15 | Sandoz Ag | Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil |
| KR100342943B1 (ko) | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
-
1999
- 1999-07-30 IN IN1036DE1999 patent/IN191496B/en unknown
-
2000
- 2000-07-24 WO PCT/IB2000/001024 patent/WO2001009143A1/en not_active Ceased
- 2000-07-24 CN CN00812246A patent/CN1371381A/zh active Pending
- 2000-07-24 AU AU58391/00A patent/AU5839100A/en not_active Abandoned
- 2000-07-24 US US10/048,354 patent/US6602999B1/en not_active Expired - Fee Related
- 2000-07-24 JP JP2001513950A patent/JP2003506329A/ja active Pending
- 2000-07-24 BR BR0012865-1A patent/BR0012865A/pt not_active Application Discontinuation
- 2000-07-24 EP EP00944159A patent/EP1204667A4/en not_active Withdrawn
-
2002
- 2002-01-25 ZA ZA200200692A patent/ZA200200692B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1371381A (zh) | 2002-09-25 |
| JP2003506329A (ja) | 2003-02-18 |
| WO2001009143A1 (en) | 2001-02-08 |
| EP1204667A4 (en) | 2002-10-30 |
| IN191496B (enExample) | 2003-12-06 |
| EP1204667A1 (en) | 2002-05-15 |
| AU5839100A (en) | 2001-02-19 |
| US6602999B1 (en) | 2003-08-05 |
| ZA200200692B (en) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012865A (pt) | Uma forma amorfa aperfeiçoada da proxetil cefpodoxima | |
| CA1037949A (en) | Cephalosporin derivatives | |
| IE831527L (en) | Preparation of azetidinooxazole derivatives | |
| WO2001073103A3 (en) | Preparation of epothilone intermediates | |
| UY23757A1 (es) | Procedimiento para la preparación de derivados de cefalosporina.- | |
| AU2003301584A1 (en) | Enzyme-catalyzed transesterifications of pendant carboxylic acid groups | |
| EP0582102B1 (en) | A method for the acylation of the 7-amino group of the cephalosporanic ring | |
| BR0112598A (pt) | Processo para a preparação de (r,s)-axetil cefuroxima cristalina de alta pureza | |
| KR100667143B1 (ko) | 가용성 측쇄 에스테르와 효소 아실라제를 사용하는 β-락탐 항균 물질의 합성법 | |
| US6919449B2 (en) | Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds | |
| CA2292618C (en) | Improved precipitation process of 7-aminocephalosporanic acid (7-aca) | |
| WO2003011871A3 (en) | Intermediates in cephalosporin production | |
| KR910018388A (ko) | 세팔로스포린 제조방방방법 | |
| GB1497039A (en) | Penicillins and cephalosporins | |
| CN100368554C (zh) | 酶催化“一锅法”制备β-内酰胺抗生素的方法 | |
| BR9301627A (pt) | Processo para preparar cefalosporinas | |
| ATE244248T1 (de) | Herstellung von amino cephalosporansäurederivaten | |
| DE60205635D1 (de) | Einfaches enzymatisches Verfahren zur Herstellung von Cefazolin | |
| FI58132B (fi) | Foerfarande foer framstaellning av 3-metyl- 3-cefem-4-karboxylsyrafoereningar | |
| EP0742219B1 (en) | Preparation and use of 7-((2-carbo-alkoxy-1-methylethenyl) amino)-3-hydroxymethyl-3-cephem-4-carboxylic acids | |
| WO2004081220A3 (en) | A process for enzymatically resolving an enantiomeric mixture of alpha-hydroxy acids | |
| US3682981A (en) | 2-amino-2-(1,4-cyclohexadienyl) acetic acid | |
| AU4757000A (en) | Method of producing methoxyimino acetic amide | |
| KR890000497A (ko) | 아실 유도체 | |
| IE46175L (en) | Preparation of 3-heterocyclylthiomethyl cephalosporins from¹3-methylene cephalosporins. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |